武田-话题@MedSci

#武田#

91篇内容 | 2923人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1517213, encodeId=0ca9151e2132f, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=日本武田制药陷虚假广告丑闻, objectType=article, longId=31543, objectId=f7b43154300, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f7b43154300, replyNumber=0, likeNumber=68, createdTime=2014-03-07, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f7b43154300, moduleTitle=日本武田制药陷虚假广告丑闻, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f7b43154300)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517212, encodeId=d3d5151e212cb, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田在日本提交TAK-438新药申请, objectType=article, longId=31514, objectId=b9643151436, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9643151436, replyNumber=0, likeNumber=72, createdTime=2014-03-07, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9643151436, moduleTitle=武田在日本提交TAK-438新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9643151436)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517211, encodeId=a720151e2117b, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田-灵北在美国推出抗抑郁药Brintellix, objectType=article, longId=29873, objectId=fbe9298e3d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbe9298e3d8, replyNumber=0, likeNumber=77, createdTime=2014-01-25, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbe9298e3d8, moduleTitle=武田-灵北在美国推出抗抑郁药Brintellix, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbe9298e3d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517210, encodeId=4eee151e21098, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田抗体偶联药物Adcetris获日本批准, objectType=article, longId=29654, objectId=c6872965429, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6872965429, replyNumber=0, likeNumber=75, createdTime=2014-01-22, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6872965429, moduleTitle=武田抗体偶联药物Adcetris获日本批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6872965429)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517209, encodeId=f101151e209be, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田制药产品研发线因Fasiglifam失败而遭受重创, objectType=article, longId=28968, objectId=778528968ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=778528968ee, replyNumber=0, likeNumber=69, createdTime=2014-01-08, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=778528968ee, moduleTitle=武田制药产品研发线因Fasiglifam失败而遭受重创, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=778528968ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517208, encodeId=0e11151e20872, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田在日本提交甲吡唑新药申请, objectType=article, longId=28636, objectId=6daa28636b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6daa28636b6, replyNumber=0, likeNumber=64, createdTime=2013-12-28, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6daa28636b6, moduleTitle=武田在日本提交甲吡唑新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6daa28636b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517207, encodeId=8391151e20705, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=FDA担忧武田旗下结肠炎试验药物Entyvio会引起PML, objectType=article, longId=27698, objectId=f6442e69879, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6442e69879, replyNumber=0, likeNumber=77, createdTime=2013-12-08, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6442e69879, moduleTitle=FDA担忧武田旗下结肠炎试验药物Entyvio会引起PML, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6442e69879)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517206, encodeId=d007151e206cb, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=EC批准武田3种糖尿病新药, objectType=article, longId=25022, objectId=6cf625022a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cf625022a2, replyNumber=0, likeNumber=63, createdTime=2013-09-28, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cf625022a2, moduleTitle=EC批准武田3种糖尿病新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cf625022a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517205, encodeId=af7a151e205f8, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=住友及武田抗精神病药Lurasidone获瑞士医药管理局批准, objectType=article, longId=23004, objectId=196723004b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=196723004b1, replyNumber=0, likeNumber=56, createdTime=2013-08-17, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=196723004b1, moduleTitle=住友及武田抗精神病药Lurasidone获瑞士医药管理局批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=196723004b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517204, encodeId=90c0151e20406, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田3种2型糖尿病新疗法获CHMP积极意见, objectType=article, longId=22558, objectId=01dc22558f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01dc22558f0, replyNumber=0, likeNumber=85, createdTime=2013-08-04, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01dc22558f0, moduleTitle=武田3种2型糖尿病新疗法获CHMP积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01dc22558f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517203, encodeId=940f151e20343, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田制药糖尿病药物Fasiglifam后期临床试验效果显著, objectType=article, longId=19364, objectId=7db6193647f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7db6193647f, replyNumber=0, likeNumber=58, createdTime=2013-05-29, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7db6193647f, moduleTitle=武田制药糖尿病药物Fasiglifam后期临床试验效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7db6193647f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

武田

2020-05-29

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

日本武田制药陷虚假广告丑闻

2014-03-07

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田在日本提交TAK-438新药申请

2014-03-07

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田-灵北在美国推出抗抑郁药Brintellix

2014-01-25

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田抗体偶联药物Adcetris获日本批准

2014-01-22

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田制药产品研发线因Fasiglifam失败而遭受重创

2014-01-08

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田在日本提交甲吡唑新药申请

2013-12-28

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

FDA担忧武田旗下结肠炎试验药物Entyvio会引起PML

2013-12-08

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

EC批准武田3种糖尿病新药

2013-09-28

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

住友及武田抗精神病药Lurasidone获瑞士医药管理局批准

2013-08-17

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田3种2型糖尿病新疗法获CHMP积极意见

2013-08-04

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田制药糖尿病药物Fasiglifam后期临床试验效果显著

2013-05-29

科室
- - 订阅+
  - 更多科室
工具
服务